FT825

FT825 is our most advanced CAR T-cell product candidate for the treatment of solid tumors, which is currently undergoing Phase 1 clinical investigation in collaboration with Ono Pharmaceutical. FT825 is an iPSC-derived, CAR T-cell product candidate targeting human epidermal growth factor receptor 2 (HER2)-expressing solid tumors, and is specifically designed to overcome challenges in treating solid tumors, such as breast, gastric, bladder, and lung cancers.

We are currently enrolling in a multi-center, Phase 1 clinical trial of FT825 for the treatment of advanced solid tumors (NCT06241456). The Phase 1 study is designed to assess the safety, tolerability, and pharmacokinetics, as well as anti-tumor activity by overall response rate, duration of response and disease control rate, of a single dose of FT825 as monotherapy and in combination with monoclonal antibody therapy.

To find out more about our clinical trials click here.

FATE Logo
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognizing you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

For more information about the data we collect please visit our Privacy Policy.